Calcium phosphate particles containing superoxide dismutase are a promising agent for the treatment of eye diseases accompanied by oxidative stress

Nikolskaya, I.I.; Безнос, О. В.; Galitskiy, V. A.; Чеснокова, Н. Б.; Кост, О. А.

doi:10.3103/s002713141603007x

Cited by 3 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the experiments in vivo demonstrated a stronger anti-inflammatory effect of SOD1 included in calcium phosphate nanoparticles compared to native SOD1 in experimental immunogenic uveitis in rabbits [150]. Namely, iris and cornea edema, edema and hyperemia of the eyelids, the amount of fibrin in the anterior chamber of the eye, and the presence of posterior synechiae decreased remarkably [150].…”

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 96%

“…Promising carriers for drug delivery are calcium carbonate and calcium phosphate [121,122,139,[146][147][148][149][150]. This is due to the biocompatibility and biodegradability of these salts [148,151], as well as the simplicity and low cost of the synthesis [123,152].…”

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

“…There are different methods of obtaining calcium-phosphate particles with various morphology and sizes: precipitation from the solutions of water-soluble salts containing phosphate anions and calcium cations [121,150,[161][162][163]; hydrothermal method using microwave radiation [164]; microemulsion method in the water/hexane/polyoxyethylene-(5)-nonylphenyl ether system [165][166][167], enzymatic hydrolysis of calcium glycerophosphate by alkaline phosphatase [168]. The simplest method is just mixing the solutions of salts containing phosphate and calcium ions with further ultrasound treatment [121,150,[161][162][163].…”

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

“…Calcium phosphate nanoparticles were shown to be able to contain both low molecular weight and high molecular weight substances. Thus, such particles containing 316 Da β-blocker timolol [121,161], 406 Da inhibitor of angiotensin-converting enzyme, lisinopril [121,122], which is also able to decrease IOP at topical instillations [169], and 32 kDa superoxide dismutase 1 [150] were reported. The particles were further coated with a disaccharide, cellobiose [122,161], or with a polysaccharide, 89 kDa chitosan [121].…”

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

“…The particles were further coated with a disaccharide, cellobiose [122,161], or with a polysaccharide, 89 kDa chitosan [121]. The particles containing different compounds were characterized by a size of 140-300 nm [121,122,150,161]. Uncoated calcium phosphate nanoparticles with encapsulated SOD1 had a negative ζpotential of about −4 mV.…”

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

See 4 more Smart Citations

Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye

Vaneev

Tikhomirova

Чеснокова

et al. 2021

IJMS

View full text Add to dashboard Cite

Topical drug delivery is one of the most challenging aspects of eye therapy. Eye drops are the most prevalent drug form, especially for widely distributed anterior segment eye diseases (cataracts, glaucoma, dry eye syndrome, inflammatory diseases, etc.), because they are convenient and easy to apply by patients. However, conventional drug formulations are usually characterized by short retention time in the tear film, insufficient contact with epithelium, fast elimination, and difficulties in overcoming ocular tissue barriers. Not more than 5% of the total drug dose administered in eye drops reaches the interior ocular tissues. To overcome the ocular drug delivery barriers and improve drug bioavailability, various conventional and novel drug delivery systems have been developed. Among these, nanosize carriers are the most attractive. The review is focused on the different drug carriers, such as synthetic and natural polymers, as well as inorganic carriers, with special attention to nanoparticles and nanomicelles. Studies in vitro and in vivo have demonstrated that new formulations could help to improve the bioavailability of the drugs, provide sustained drug release, enhance and prolong their therapeutic action. Promising results were obtained with drug-loaded nanoparticles included in in situ gel.

show abstract

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 96%

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

Section: Particles Formed By Inorganic Saltsmentioning

confidence: 99%

See 3 more Smart Citations

Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye

Vaneev

Tikhomirova

Чеснокова

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye

Попова

Tikhomirova

Безнос

et al. 2022

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

Chitosan-Covered Calcium Phosphate Particles Co-Loaded with Superoxide Dismutase 1 and ACE Inhibitor: Development, Characterization and Effect on Intraocular Pressure

et al. 2023

View full text Add to dashboard Cite

Improvement of the efficiency of drug penetration into the eye tissues is still an actual problem in ophthalmology. One of the most promising solutions is drug encapsulation in carriers capable of overcoming the cornea/sclera tissue barrier. Formulations on the base of antioxidant enzyme, superoxide dismutase 1 (SOD1), and an inhibitor of angiotensin-converting enzyme, enalaprilat, were prepared by simultaneous inclusion of both drugs into calcium phosphate (CaP) particles in situ with subsequent covering of the particles with 5 kDa chitosan. The formulations obtained were characterized by dynamic light scattering and scanning electron microscopy. Hybrid CaP-chitosan particles co-loaded with SOD1 and enalaprilat had a mean hydrodynamic diameter of 120–160 nm and ζ-potential +20 ± 1 mV. The percentage of the inclusion of SOD1 and enalaprilat in hybrid particles was 30% and 56%, respectively. The ability of SOD1 and enalaprilat to reduce intraocular pressure (IOP) was examined in vivo in normotensive Chinchilla rabbits. It was shown that topical instillations of SOD1/enalaprilat co-loaded hybrid particles were much more effective in decreasing IOP compared to free enzyme or free enalaprilat and even to the same particles that contained a single drug. Thus, the proposed formulations demonstrate potential as prospective therapeutic agents for the treatment of glaucoma.

show abstract

Calcium phosphate particles containing superoxide dismutase are a promising agent for the treatment of eye diseases accompanied by oxidative stress

Cited by 3 publications

References 12 publications

Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye

Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye

Chitosan-covered calcium phosphate particles as a drug vehicle for delivery to the eye

Chitosan-Covered Calcium Phosphate Particles Co-Loaded with Superoxide Dismutase 1 and ACE Inhibitor: Development, Characterization and Effect on Intraocular Pressure

Contact Info

Product

Resources

About